Source comparison
MK-677 Results Timeline: Clinical vs Anecdotal Comparison
Week 1–2 50% increase in slow-wave sleep duration; IGF-1 elevation peaks day 14 Improved sleep quality, faster inter-session recovery, reduced joint discomfort Sleep architecture changes are real and immediate—this is the first reliable marker that the compoun
This comparison does not assign a generated winner or score.
- Week 1–2
- 50% increase in slow-wave sleep duration; IGF-1 elevation peaks day 14
- Improved sleep quality, faster inter-session recovery, reduced joint discomfort
- Sleep architecture changes are real and immediate—this is the first reliable marker that the compound is active.
- Week 3–6
- Positive nitrogen retention by day 21; glycogen storage capacity increases 10–15%
- Noticeable muscle fullness, slight vascularity increase, strength plateau breaks for some users
- Visual changes are mostly intramuscular water and glycogen—not yet lean tissue accrual. Training stimulus determines whether this translates to hypertrophy.
- Week 8–12
- 1.1kg lean mass gain at week 8 (DEXA-verified); fasting glucose +8 mg/dL average
- Fat loss becomes apparent in deficit; some users report water retention in extremities
- Body recomposition becomes measurable—but only if caloric intake and training volume are structured correctly. Standalone use without deficit yields minimal fat loss.
- Week 12–16+
- 2.3kg lean mass gain by week 16; partial reversal of insulin resistance after week 8
- Strength increases 5–10% on compound lifts; stubborn fat areas respond more readily to deficit
- This is where the compound justifies its use—sustained GH/IGF-1 elevation over 12+ weeks produces outcomes diet and training alone don't replicate in the same timeframe.